428 related articles for article (PubMed ID: 23393388)
1. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
3. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
4. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
5. PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.
Zhang LL; Gao CY; Fang CQ; Wang YJ; Gao D; Yao GE; Xiang J; Wang JZ; Li JC
Cardiovasc Res; 2011 Dec; 92(3):484-93. PubMed ID: 21880694
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
7. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
8. Smooth Muscle Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Formation and Rupture of Cerebral Aneurysms in Mice In Vivo.
Hasan DM; Starke RM; Gu H; Wilson K; Chu Y; Chalouhi N; Heistad DD; Faraci FM; Sigmund CD
Hypertension; 2015 Jul; 66(1):211-20. PubMed ID: 25916724
[TBL] [Abstract][Full Text] [Related]
9. Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease.
Marchesi C; Rehman A; Rautureau Y; Kasal DA; Briet M; Leibowitz A; Simeone SM; Ebrahimian T; Neves MF; Offermanns S; Gonzalez FJ; Paradis P; Schiffrin EL
Cardiovasc Res; 2013 Mar; 97(3):562-70. PubMed ID: 23250918
[TBL] [Abstract][Full Text] [Related]
10. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
11. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma.
Ketsawatsomkron P; Sigmund CD
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):123-30. PubMed ID: 25587903
[TBL] [Abstract][Full Text] [Related]
13. Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.
Carrillo-Sepulveda MA; Keen HL; Davis DR; Grobe JL; Sigmund CD
PLoS One; 2014; 9(8):e103786. PubMed ID: 25122005
[TBL] [Abstract][Full Text] [Related]
14. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells.
Min Q; Bai YT; Jia G; Wu J; Xiang JZ
Exp Mol Pathol; 2010 Feb; 88(1):133-7. PubMed ID: 19796634
[TBL] [Abstract][Full Text] [Related]
15. Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARγ).
Krskova K; Filipcik P; Zilka N; Olszanecki R; Korbut R; Gajdosechova L; Zorad S
J Physiol Pharmacol; 2011 Aug; 62(4):403-10. PubMed ID: 22100841
[TBL] [Abstract][Full Text] [Related]
16. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
Ren L; Liu N; Zhi H; Li Y; Li Y; Tang R; Sheng Z
Cardiovasc Diabetol; 2011 Jan; 10():10. PubMed ID: 21269478
[TBL] [Abstract][Full Text] [Related]
17. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
[TBL] [Abstract][Full Text] [Related]
19. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors.
Lemarié CA; Simeone SM; Nikonova A; Ebrahimian T; Deschênes ME; Coffman TM; Paradis P; Schiffrin EL
Circ Res; 2009 Oct; 105(9):852-9. PubMed ID: 19762686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
